| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-07 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.21 | 2e-06 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-06 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |